myeloma

Treatment advances in myeloma now benefiting other blood cancers

harminka — Fri, 12 Sep 2008 07:50:36 -0500

The International Myeloma Foundation (IMF)—supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians—today said survival outcomes have improved dramatically for patients with multiple myeloma, cancer in the bone marrow that affects blood cell production.

Treatment with anti-anemia drugs may not be safe for multiple myeloma patients

harminka — Tue, 05 Aug 2008 04:57:51 -0500

A recent study published in American Journal of Hematology demonstrated that Erythropoiesis-stimulating agents (ESAs), a widely used drug to treat anemia, may have a negative impact on the survival of myeloma patients.

New therapeutic options for newly diagnosed multiple myeloma patients

harminka — Mon, 10 Dec 2007 14:05:34 -0600

Mayo Clinic researchers today presented results of a phase II trial of myeloma induction therapy -- a first step therapy designed to reduce cancer cells numbers -- with cyclophosphamide, bortezomib, and dexamethasone (Cybor-D) showing an improved response over the traditional lenalidomide-dexamethasone (L-Dex) therapy.

New Survival Standard for Bone Marrow Cancer

harminka — Thu, 22 Nov 2007 07:51:33 -0600

Findings from two large, international clinical trials show “unprecedented” survival for patients with multiple myeloma, a blood cancer that occurs in the blood-making cells of bone marrow. The findings demonstrate that with Revlimid®, an oral cancer drug, all measures of myeloma showed significant improvement in patients where previous treatments had failed.

Human C-reactive protein regulates myeloma tumor cell growth

harminka — Mon, 10 Sep 2007 12:55:30 -0500

Scientists report that a protein best known as a common marker of inflammation plays a key role in the progression of human cancer. The research, published by Cell Press in the September issue of the journal Cancer Cell, implicates C-reactive protein (CRP) as a potential target for cancer treatment.

Changing way physicians treat multiple myeloma

harminka — Tue, 05 Jun 2007 04:13:00 -0500

Moffitt clinical director part of National Myeloma Forum recommending additional studies that further evaluate new front-line oral Revlimid treatment combinations as an alternative to stem cell transplant in newly diagnosed patients

Transplantation does not benefit patients with refractory myeloma

harminka — Tue, 05 Jun 2007 03:47:42 -0500

This clinical study demonstrates that in patients who do not respond to previous chemotherapy procedures, autologous bone-marrow transplantation does not guarantee higher survival rates

Researchers identify pathways mediating myeloma treatment side effects

harminka — Mon, 11 Dec 2006 13:35:54 -0600

Drug combination proves effective against myeloma in Phase I trial

harminka — Mon, 11 Dec 2006 13:28:35 -0600

Individualizing Treatment for Multiple Myeloma Patients

harminka — Sun, 10 Dec 2006 10:30:44 -0600